Radiotherapeutic treatment of Peyronie´s disease

References

• de la Peyronie PG. Sur quelques obstacles qui s'opposent a l'ejaculation naturelle de la semence. Mem. Acad. R. Chir. 1,425–434 (1743).
   Google Scholar
• Hauck EW, Weidner W Francois de la Peyronie and the disease named after him. Lancet357, 2049–2051 (2001).
   PubMedGoogle Scholar
• Sommer F, Schwarzer U, Wassmer G et al Epidemiology of Peyronie's disease. int. J. Impot. Res. 14,379–383 (2002).
   PubMed Web of Science ®Google Scholar
• La Pera G, Pescatori ES, Calabrese M et al Peyronie's disease: prevalence and association with cigarette smoking. Eur Ural 40,525–530 (2001).
   PubMed Web of Science ®Google Scholar
• Lyles KW, Goldt DT, Newton RA et al Peyronie's disease is associated with Paget's disease of bone.J Bone Min. Res. 12, 929–934 (1997).
   PubMed Web of Science ®Google Scholar
• Carrieri MP, Serraino D, Palmiotto F, Nucci G, Sasso E A case-control study on risk factors for Peyronie's disease. J. Gun. Epidemiol. 51, 511–515 (1998).
   Google Scholar
• •Highlights the risk factors for Peyronie's disease (PD).
   Google Scholar
• Ralph DJ, Schwartz G, Moore W, Pryor JP, Ebringer A, Bottazzo GE The genetic and bacteriological aspects of Peyronie's disease. J. Ural 157,291–294 (1997).
   PubMed Web of Science ®Google Scholar
• Brock G, Hsu GL, Nunes L, von Heyden B, Luc TF. The anatomy of the tunica albuginea in the normal penis and Peyronie's disease. J. Ural 157,276–281 (1997).
   Google Scholar
• Devine CJ, Somers KD, Jordan GH, Schlossberg SM. Proposal: trauma as the cause of the Peyronie's lesion. J. Ural 157, 285–290 (1997).
   PubMed Web of Science ®Google Scholar
• Jarow JP, Lowe PC. Penile trauma: an etiologic factor in Peyronie's disease and erectile dysfunction. J. Ural 158, 1388–1390 (1997).
   PubMed Web of Science ®Google Scholar
• Davis CJ Jr. The microscopic pathology of Peyronie's disease. J Ural 157,282–284 (1997).
   PubMedGoogle Scholar
• Somers KD, Dawson DM. Fibrin deposition in Peyronie's disease plaque. J. Ural 157,311–315 (1997).
   PubMed Web of Science ®Google Scholar
• Diegelmann RE Cellular and biochemical aspects of normal and abnormal wound healing: an overview. J Ural 157,298–302 (1997).
   PubMed Web of Science ®Google Scholar
• Ehrlich HP Scar contracture: cellular and connective tissue aspects in Peyronie's disease. Uml. 157,316–319 (1997).
   Google Scholar
• Magee TR, Qian A, Rajfer J et al. Gene expression profiles in the Peyronie's disease plaque. Urology59,451–457 (2002).
   PubMed Web of Science ®Google Scholar
• Moreland RB, Nehra A. Pathofysiology of Peyronie's disease. Int. J Impot. Res. 14, 406–410 (2002).
   PubMed Web of Science ®Google Scholar
• Devine CJ, Horton CE. Peyronie's disease. Clin. Rast. Surg. 15,405–409 (1988).
   Google Scholar
• Gelbard MK, Dorey F, James K. The natural history of Peyronie's disease. J Ural 144,1376–1379 (1990).
   Google Scholar
• Pryor JP, Ralph DJ. Clinical presentation of Peyronie's disease. Int. J Impot. Res. 14, 414–417 (2002).
   PubMed Web of Science ®Google Scholar
• Lue TF, Gelbard MK, Gueglio G et al Peyronie's disease. In: Erectile Dysfunction. Jardin A, Wagner G, Khoury S, Giuliano F, Padma-Nathan H, Rosen R (Eds). Health Publication Limited, Plymouth, UK, 439–475 (2000).
   Google Scholar
• ••Comprehensive overview on PD.
   Google Scholar
• Hakim LS. Peyronie's disease: an update. The role of diagnostics. Int. J Impot. Res. 14,321–323 (2002).
   PubMedGoogle Scholar
• Hauck EW, Hackstein N, Vosshenrich R et al Diagnostic value of magnetic resonance imaging in Peyronie's disease — a comparison both with palpation and ultrasound in the evaluation of plaque formation. Eur Ural 43,293–300 (2003).
   PubMedGoogle Scholar
• Lopez JA, Jarow JR Penile vascular evaluation of men with Peyronie's disease. J Ural 149,53–55 (1993).
   PubMed Web of Science ®Google Scholar
• Montorsi F, Guazzoni G, Bergamaschi F et al Vascular abnormalities in Peyronie's disease: the role of color Doppler sonography. I Ural 151,373–375 (1994).
   Google Scholar
• Weidner W Schroeder-Printzen I, Weiske WF, Vosshenrich R. Sexual dysfunction in Peyronie's disease: an analysis of 222 patients without previous plaque therapy. J. Ural 157,325–328 (1997).
   Google Scholar
• Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF). A multidimensional scale for assessment of erectile dysfunction. Urology 49,822–830 (1997).
   Google Scholar
• Scott WW Scardino PL. A new concept in the treatment of Peyronie's disease. South Med j41, 173–177 (1948).
   PubMedGoogle Scholar
• Wagenknecht LV. Differential therapies in various stages of penile induration. Alch Esp. Ural 49,285–292 (1996).
   PubMedGoogle Scholar
• Akkus E, Carrier S, Rehman J, Breza J, Kadioglu A, Lue TE Is colchicine effectieve in Peyronie's disease? A pilot study. Urology 44,291–295 (1997).
   Google Scholar
• Kadioglu A, Tefekli A, Köksal T, Usta M, Erol H. Treatment of Peyronie's disease with oral colchicine: Long-term results and predictive parameters of successful outcome. Int. Impot. Res. 12,169-175 (2000).
   Google Scholar
• Prieto Castro RM, Leva Vallejo ME, Lopez Regueiro JC, Anglada Curado FJ, Alvarez Kindelan J, Requena Tapia MJ. Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease. BJU Int. 91,522–524 (2003).
   PubMed Web of Science ®Google Scholar
• Ralph DJ, Brooks MD, Bottazzo GF, Pryor JR The treatment of Peyronie's disease with tamoxifen. Br. Ural 70,648–651 (1992).
   PubMedGoogle Scholar
• Teloken C, Rhoden EL, Grazziottin TM, Da Ros CT, Sogari PR, Souto CAV. Tamoxifen versus placebo in the treatment of Peyronie's disease. J. Ural 162, 2003–2005 (1999).
   Google Scholar
• Gelbard MK, James K, Riach P, Dow E Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study. J. Ural 149,56–58 (1993).
   PubMed Web of Science ®Google Scholar
• Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie's disease. J. Ural 151, 1522–1524 (1994).
   Google Scholar
• Levine LA. Treatment of Peyronie's disease with intralesional verapamil injection. J. Ural 158,1395–1399 (1997).
   PubMed Web of Science ®Google Scholar
• Levine AL, Goldman KE, Greenfield JM. Experience with intraplaque injection of verapamil for Peyronie's disease. I Uml. 168,621–626 (2002).
   Google Scholar
• Cavallini G, Biagiotti G, Koverech A, Vitali G. Oral propionyl-L-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease. BJU Int. 89,895–900 (2002).
   PubMed Web of Science ®Google Scholar
• Wegner H, Andresen R, Knispel H, Miller K. Treatment of Peyronie's disease with local interferon-CL 2b. Eur. Ural 28, 236–240 (1995).
   Google Scholar
• Judge IS, Wisniewski ZS. Intralesional interferon in the treatment of Peyronie's disease: a pilot study. BE J. Ural 79,40–42 (1997).
   PubMedGoogle Scholar
• Brake N, Loertzer H, Horsch R, Keller H. Treatment of Peyronie's dismse with local interferon-a 2b. BJU Int. 87,654–657 (2001).
   PubMed Web of Science ®Google Scholar
• Lebret T, Loison G, Hervé JM et al Extracorporeal shock wave therapy in the treatment of Peyronie's disease: Experience with standard lithotriptor (Siemens-multiline) . Urology59,657–661 (2002).
   PubMedGoogle Scholar
• Manikandan R, Islam W, Srinivasan V, Evans CM. Evaluation of extracorporeal shock wave therapy in Peyronie's disease. Urology60, 795–800 (2002).
   PubMedGoogle Scholar
• Hamm R, McLarty E, Ashdown J, Natale S, Dickinson A. Peyronie's disease — the Plymouth experience of extracorporeal shockwave treatment. BJU Int. 87, 849–852 (2001).
   Google Scholar
• Husain J, Lynn NNK, Jones DK, Collins GN, O'Reilly PH. Extracorporeal shock wave therapy in the management of Peyronie's disease: initial experience. BJU Int. 86,466–468 (2000).
   PubMed Web of Science ®Google Scholar
• Kelami A. Classification of congenital and acquired penile deviation. Ural Int. 38, 229–233 (1983).
   PubMedGoogle Scholar
• Pryor J, Fitzpatrick J. A new approach to the correction of the penile deformity in Peyronie's disease. J. Ural 122,622–623 (1979).
   PubMedGoogle Scholar
• Ralph D, Al-Akraa M, Pryor J. The Nesbit operation for Peyronie's disease: 16- year experience. Ural 154,1362–1363 (1995).
   PubMed Web of Science ®Google Scholar
• Levine LA, Lenting EL. A surgical algorithm for the treatment of Peyronie's disease.' Ural 158,2149–2152 (1997).
   PubMed Web of Science ®Google Scholar
• Trott KR, Kamprad E Radiobiological mechanisms of anti-inflammatory radiotherapy. Radiother. Oncol 51, 197–203 (1999).
   PubMed Web of Science ®Google Scholar
• Leer JWH, van Houtte P, Davelaar J. Indications and treatment schedules for irradiation of benign disease: a survey. Radiother Oncol 48,249–257 (1998).
   PubMedGoogle Scholar
• Fricke RE, Olds JW. The radium treatment of Peyronie's disease. AJR 42, 545–550 (1939).
   Google Scholar
• Dahl O. Treatment of plastic induration of penis (Peyronie's disease). Acta Radiol. 41, 290–301 (1954).
   PubMed Web of Science ®Google Scholar
• Duggan HE. Effect of x-ray therapy on patients with Peyronie's disease. I Um/. 91, 572–574 (1964).
   Google Scholar
• Dunlap JC, Lathem JE. X-ray therapy in Peyronie's disease. South Med. J. 62,1485–1486 (1969).
   PubMedGoogle Scholar
• Griff LC. Peyronie's disease. The role of radiation therapy and a general review. AIR 100,916–919 (1967).
   Google Scholar
• Williams JL, Thomas GG. The natural history of Peyronie's disease. J Ural 103, 75–76 (1970).
   PubMed Web of Science ®Google Scholar
• Helvie WW Fiske Ochsner S. Radiation therapy in Peyronie's disease. South Med. J 65, 1192–1996 (1972).
   PubMedGoogle Scholar
• Martin CL. Long time study of patients with Peyronie's disease treated with irradiation. AJR114, 492–497 (1972).
   Google Scholar
• Poutasse EF. Peyronie's disease. J Ural 107, 419–422 (1972).
   PubMedGoogle Scholar
• Furlow WL, Swenson HE Jr, Lee RE. Peyronie's disease: a study of its natural history and treatment with orthovoltage radiotherapy. J th-ol. 114, 69–71 (1975).
   Google Scholar
• Carson CC, Coughlin PWF. Radiation therapy for Peyronie's disease: is there a place?' Ural 134, 684–686 (1985).
   PubMed Web of Science ®Google Scholar
• •Highlights the critical aspects of radiotherapy for PD.
   Google Scholar
• Mira JG, Chahbazian CM, del Regato JA. The value of radiotherapy for Peyronie's disease: presentation of 56 new case studies and review of the literature. Int. J Radiat. Oiled Biol. iiyc. 6, 161–166 (1980).
   Google Scholar
• Viljoen IM, Goedhals L, Doman MJ. Peyronie's disease — a perspective on the disease and the long-term results of radiotherapy. S. Afr. Med 83, 19–20 (1993).
   Google Scholar
• Rodrigues CI, Njo KH, Karim ABME Results of radiotherapy and vitamin E in the treatment of Peyronie's disease. Int. J Radiat. Onto]. Biol. Phyc 31, 571–576 (1995).
   PubMedGoogle Scholar
• Incrocci L, Wijnmaalen A, Slob AK, Hop WCJ, Levendag PC. Low-dose radiotherapy in 179 patients with Peyronie's disease: treatment outcome and current sexual functioning. Int. J Radiat. amyl Biol. Phys. 47, 1353–1356 (2000).
   Google Scholar
• Incrocci L, Hop WCJ, Slob AK. Current sexual functioning in 106 patients with Peyronie's disease, treated with radiotherapy 9 years earlier. Urology56, 1030–1034 (2000).
   Google Scholar
• •Extensively addresses the sexual functioning of patients with PD after radiotherapy.
   Google Scholar